GlassScriptPhysician profile
Nancy Stepanek
NPI 1861624843
$7,580.26
in general payments reported to CMS, 2019-2025
33 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,421 · 2022: $1,125 · 2023: $1,425 · 2024: $1,514 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $804.60 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbott Laboratories | $790.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $660.24 | 2021-2025 | Rexulti |
| Abbvie INC. | $623.00 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $565.97 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $565.14 | 2022-2024 | Airsupra, Fasenra, Farxiga |
| Lundbeck LLC | $385.34 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $297.23 | 2021-2022 | |
| Edwards Lifesciences Corporation | $260.59 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic, INC. | $241.65 | 2022-2025 | Pulseselect |
| Neurocrine Biosciences, INC. | $223.87 | 2021-2023 | |
| Glaxosmithkline, LLC. | $209.04 | 2022 | |
| Novo Nordisk INC | $207.51 | 2022-2025 | Ozempic |
| Alkermes, INC. | $199.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $177.24 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $176.67 | 2024-2025 | Qutenza |
| Amgen INC. | $143.48 | 2021-2025 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $134.90 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $132.73 | 2023-2024 | |
| Tempus Ai, INC | $124.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.07 | 2022 | |
| Coloplast Corp | $110.55 | 2023 | Titan, Altis |
| Idorsia Pharmaceuticals US INC | $96.66 | 2022 | |
| Bausch Health US, LLC | $72.82 | 2021-2022 | |
| Indivior INC. | $49.18 | 2021 | |
| Corium, LLC | $47.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.80 | 2021-2022 | |
| Dexcom, INC. | $34.22 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.70 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.78 | 2021 | |
| Merck Sharp & Dohme LLC | $14.45 | 2021 | |
| Eisai INC. | $12.59 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Stepanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.